RAPT Therapeutics (RAPT)
RAPT · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Oncologysrc
Signal Snapshot
1
Clinical Trial (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
1 Phase 2
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer. — J Immunother Cancer (2026) PMID 42759982
- Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. — Lancet (2026) PMID 42628554
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for RAPT Therapeutics.
Full RAPT Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.